CP
XLO icon

Caligan Partners’s Xilio Therapeutics XLO Stock Holding History

Caligan Partners’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$943K Buy
+112,128
New +$918K 0.06% 28

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Caligan Partners's XLO Position: Q1 2026 in Review

Caligan Partners opened a new position in Xilio Therapeutics (XLO) in Q1 2026: 112,128 shares worth $943K. The stake represents 0.06% of the portfolio and ranks #28 among its holdings.

24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Caligan Partners held 112,128 shares of Xilio Therapeutics worth $943K as of Q1 2026.
  • Xilio Therapeutics was a new Caligan Partners position in Q1 2026.
  • Xilio Therapeutics made up 0.06% of Caligan Partners's portfolio in Q1 2026, its #28 holding.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Caligan Partners's 13F filing for Q1 2026, filed 15 May 2026.